Join
Live feed
·
PRReleasevia Quantisnow
60 Degrees Pharmaceuticals Inc. logo

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

ByQuantisnow·Wall Street's wire, on your screen.
SXTP· 60 Degrees Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SXTP (60 Degrees Pharmaceuticals Inc.) and more on Quantisnow.